Although many molecular biomarkers are linked to glioma, such as isocitrate dehydrogenase enzyme 1/2 (IDH1/2) mutation and epidermal growth factor receptor (EGFR) overexpression, their reliability and clinical significance are still controversial and need more research (Thakkar et al., 2014; Alexander and Cloughesy, 2017). Here, EGFR is linked to central nervous system cancer.